Patient Characteristics
| Characteristic | All patients (n = 25) | Hybrid-tracer group (n = 15) | Free-ICG group (n = 10) | P |
| Age at surgery (y) | 65.4 (6.1) | 64.3 (8.4) | 67.4 (4.4) | 0.247 |
| PSA at diagnosis | 8.6 (3.9) | 9.1 (4.6) | 7.7 (2.3) | 0.383 |
| PSA range at diagnosis (ng/mL) | 2.7–22.5 | 2.7–22.5 | 4.31–12.04 | |
| Clinical stage | 0.870 | |||
| cT1c | 5 | 4 | 1 | |
| cT2a | 4 | 2 | 2 | |
| cT2b | 3 | 1 | 2 | |
| cT2c | 7 | 4 | 3 | |
| cT3a | 5 | 3 | 2 | |
| cT3b | 1 | 1 | 0 | |
| Biopsy Gleason sum | 1.000 | |||
| 6 | 2 | 1 | 1 | |
| 7 | 17 | 10 | 7 | |
| 8 | 3 | 2 | 1 | |
| 9 | 3 | 2 | 1 | |
| Prostate volume (mL) | 50.2 (21) | 48.1 (20.0) | 52.4 (25.8) | 0.641 |
| Briganti score | 16.6% (16.1) | 16.6 (15.6) | 16.6 (17.8) | 0.996 |
| Pathologic stage | 0.596 | |||
| pT2a | 4 | 1 | 3 | |
| pT2c | 14 | 9 | 5 | |
| pT3a | 5 | 3 | 2 | |
| pT3b | 1 | 1 | 0 | |
| pT4 | 1 | 1 | 0 | |
| Pathologic Gleason sum | 0.194 | |||
| 6 | 3 | 3 | 0 | |
| 7 | 15 | 7 | 8 | |
| 8 | 3 | 3 | 0 | |
| 9 | 2 | 2 | 2 | |
| Nodal status | 1.00 | |||
| pN0 | 19 | 11 | 8 | |
| pN1 | 6 | 4 | 2 |
Qualitative data are expressed as numbers; continuous data are expressed as mean followed by SD in parentheses.